MedTrace Logo

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

NCT04485663 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2022-03-15

No results posted yet for this study

Summary

A Randomized Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Conditions

Interventions

DRUG

ALG-010133

Single or multiple doses of ALG-010133

DRUG

Placebo

Single or multiple doses of Placebo

Sponsors & Collaborators

  • Aligos Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-17
Primary Completion
2022-03-08
Completion
2022-03-08

Countries

  • China
  • Hong Kong
  • Moldova
  • New Zealand
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04485663 on ClinicalTrials.gov